Cosentyx (secukinumab) is a biologic drug used to treat various inflammatory conditions, including psoriasis and psoriatic arthritis. As with any medication, there are potential long-term risks associated with its use.

One study published in the Journal of Rheumatology found that patients treated with Cosentyx for up to five years had a low incidence of serious adverse events, and the drug was generally well-tolerated [3]. However, the study did note that long-term safety data is still limited and further research is needed to fully understand the potential risks associated with the drug.

Another study published in Arthritis Research & Therapy found that patients treated with Cosentyx for up to three years had sustained improvements in disease activity and quality of life, with a low incidence of adverse events [2]. The study also noted that long-term safety data is still limited and further research is needed.

According to Drug Patent Watch, the patent for Cosentyx is set to expire in 2026 [1]. This means that other companies will be able to produce and sell generic versions of the drug, which may lead to increased competition and potentially lower prices for patients.

In summary, while current studies suggest that Cosentyx is generally well-tolerated and effective in treating inflammatory conditions, there is still limited long-term safety data available. Patients should discuss the potential risks and benefits of the drug with their healthcare provider before starting treatment.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-1882-2
[3] https://pubmed.ncbi.nlm.nih.gov/35146532/